Supernus Pharmaceuticals SUPN Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Product | ||||||
| APOKYN | $40.52M-43.9% | $47.77M-35.4% | $58.3M-19.7% | $67.78M-8.7% | $72.25M-3.0% | |
| Collaboration revenue (ZURZUVAE) | $80.64M— | $53M— | $20.16M— | $0— | —— | |
| GOCOVRI | $151.38M+12.2% | $146.82M+12.2% | $145.1M+15.2% | $139.91M+13.6% | $134.95M+12.3% | |
| ONAPGO | $25.63M— | $17.25M— | $8.41M— | $1.6M— | $0— | |
| Other | $23M-24.3% | $26.91M-7.2% | $29.09M-4.1% | $29.36M-3.0% | $30.37M-0.8% | |
| Oxtellar XR | $37.92M-54.2% | $40.7M-59.1% | $47.05M-59.9% | $64.84M-44.7% | $82.72M-25.8% | |
| Qelbree | $317.75M+21.8% | $304.65M+26.3% | $298.12M+39.8% | $279.07M+48.5% | $260.92M+63.6% | |
| Royalty, licensing, and other revenues | $60.89M+127% | $39.42M+63.4% | $26.46M+7.3% | $28.45M+17.8% | $26.77M+4.7% | |
| Trokendi XR | $39.1M-34.8% | $42.42M-32.9% | $48.85M-28.2% | $54.12M-26.2% | $60.01M-20.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Supernus Pharmaceuticals break its business down?
- Supernus Pharmaceuticals (SUPN) reports total revenues by product across 9 parts — APOKYN, Collaboration revenue (ZURZUVAE), GOCOVRI, ONAPGO and Other. Each is extracted from the segment footnotes and tracked over time.
- Where does Supernus Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Supernus Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
